In Q1 2026, Ultragenyx reported revenue below expectations with a widened net loss, attributed partly to seasonal sales effects and operational restructuring. Despite near-term financial headwinds, the company made critical pipeline progress including FDA acceptance of a key gene therapy biologics license application (BLA). Ultragenyx continues to rely on its rare disease focus and gene therapy R&D to drive future growth amidst manufacturing and regulatory challenges.